Signalling pathways and mechanisms of protection in pre- and postconditioning: Historical perspective and lessons for the future

British Journal of Pharmacology

Volumn 172, Issue 8, 2015, Pages 1913-1932

  Cohen, Michael V ^a   Downey, James M ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; BRADYKININ; CANGRELOR; CLOPIDOGREL; FIBRINOLYTIC AGENT; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; INHALATION ANESTHETIC AGENT; LIGAND; NITRIC OXIDE; OPIATE; PHOSPHOLIPID; POTASSIUM CHANNEL; PRASUGREL; PROTEIN KINASE C; PURINERGIC P2Y12 RECEPTOR; REACTIVE OXYGEN METABOLITE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; TICAGRELOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; ANESTHETIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOTONIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL PERMEABILITY; PLATELET REACTIVITY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ANIMAL; HEART INFARCTION PREVENTION; HISTORY; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANESTHETICS; ANIMALS; CARDIOTONIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84925852648     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12903     Document Type: Review

References (203)

1. 2b receptor activation mimics postconditioning in a rabbit infarct model. Circulation 114 (Suppl. II): II-14-II-15.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
7. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJC, Frech M, et al. (1997). Role of translocation in the activation and function of protein kinase B. J Biol Chem 272: 31515-31524.
8. Antiplatelet Trialists' Collaboration (1994). Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106.
9. APEX AMI Investigators, Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, et al. (2007). Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297: 43-51.
10. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M, (2005). Postconditioning inhibits mitochondrial permeability transition. Circulation 111: 194-197.
11. Baines CP, Goto M, Downey JM, (1997). Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 29: 207-216.
12. ATP channels in the isolated rabbit heart. Basic Res Cardiol 94: 188-198.
13. Barrabés JA, Garcia-Dorado D, Mirabet M, Lidõn R-M, Soriano B, Ruiz-Meana M, et al. (2002). Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol 39: 157-165.
14. 12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 104: 128-135.
15. Baxter GF, (2004). Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol 99: 90-93.
16. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM, (2001). Cardioprotective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 38: 930-939.
17. Becker LB, Vanden Hoek TL, Shao Z-H, Li C-Q, Schumacker PT, (1999). Generation of superoxide in cardiomyocytes during ischemia before reperfusion. Am J Physiol Heart Circ Physiol 277: H2240-H2246.
18. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. (2013). Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368: 1303-1313.
19. Birnbaum Y, Mahaffey KW, Criger DA, Gates KB, Barbash GI, Barbagelata A, et al. (2002). Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. Cardiology 97: 166-174.
20. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R, (2010). Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105: 771-785.
21. Budde JM, Velez DA, Zhao Z-Q, Clark KL, Morris CD, Muraki S, et al. (2000). Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res 47: 294-305.
22. Burley DS, Ferdinandy P, Baxter GF, (2007). Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 152: 855-869.
23. Cai Z, Semenza GL, (2004). Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109: 2050-2053.
24. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC, (2005). Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102: 102-109.
25. Cleland JGF, Coletta AP, Torabi A, Ahmed D, Clark AL, (2010). Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III. Eur J Heart Fail 12: 1261-1264.
26. ATP channels. Circ Res 89: 273-278.
27. Cohen MV, Yang X-M, Downey JM, (2006). Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res 70: 231-239.
28. Cohen MV, Philipp S, Krieg T, Cui L, Kuno A, Solodushko V, et al. (2007a). Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. J Mol Cell Cardiol 42: 842-851.
29. Cohen MV, Yang X-M, Downey JM, (2007b). The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 115: 1895-1903.
30. Cohen MV, Yang X-M, Downey JM, (2008). Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 103: 464-471.
31. Cope DK, Impastato WK, Cohen MV, Downey JM, (1997). Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology 86: 699-709.
32. ATP, PKCε, ROS, and MPT. Am J Physiol Heart Circ Physiol 295: H874-H882.
33. Costa ADT, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, et al. (2005). Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329-336.
34. Costa ADT, Pierre SV, Cohen MV, Downey JM, Garlid KD, (2008). cGMP signalling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res 77: 344-352.
35. + and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276: 2571-2575.
36. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
37. Dorn GW, Souroujon MC, Liron T, Chen C-H, Gray MO, Zhou HZ, et al. (1999). Sustained in vivo cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation. Proc Natl Acad Sci U S A 96: 12798-12803.
38. Dost T, Cohen MV, Downey JM, (2008). Redox signaling triggers protection during the reperfusion rather than the ischemic phase of preconditioning. Basic Res Cardiol 103: 378-384.
39. Downey JM, Cohen MV, (2009). Why do we still not have cardioprotective drugs? Circ J 73: 1171-1177.
40. ATP channel opening. Am J Physiol Heart Circ Physiol 284: H1592-H1600.
41. 2B adenosine receptors. Circulation 115: 1581-1590.
42. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard J-C, Zaugg M, (2005). Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3β. Anesthesiology 103: 987-995.
43. Forbes RA, Steenbergen C, Murphy E, (2001). Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 88: 802-809.
44. Förster K, Paul I, Solenkova N, Staudt A, Cohen MV, Downey JM, et al. (2006). NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol 101: 319-326.
45. Freixa X, Bellera N, Ortiz-Pérez JT, Jiménez M, Paré C, Bosch X, et al. (2012). Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 33: 103-112.
46. Frias MA, Lecour S, James RW, Pedretti S, (2012). High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: role of STAT3 as part of the SAFE pathway. JAKSTAT 1: 92-100.
47. Garlid AO, Jaburek M, Jacobs JP, Garlid KD, (2013). Mitochondrial reactive oxygen species: which ROS signals cardioprotection? Am J Physiol Heart Circ Physiol 305: H960-H968.
48. + channels: possible mechanism of cardioprotection. Circ Res 81: 1072-1082.
49. Garlid KD, Costa ADT, Quinlan CL, Pierre SV, Dos Santos P, (2009). Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 46: 858-866.
50. Gateau-Roesch O, Argaud L, Ovize M, (2006). Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 70: 264-273.
51. Goto M, Miura T, Iliodoromitis EK, O'Leary EL, Ishimoto R, Yellon DM, et al. (1991). Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 25: 943-949.
52. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM, (1995). Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77: 611-621.
53. Goto M, Cohen MV, Van Wylen DGL, Downey JM, (1996). Attenuated purine production during subsequent ischemia in preconditioned rabbit myocardium is unrelated to the mechanism of protection. J Mol Cell Cardiol 28: 447-454.
54. Griffiths EJ, Halestrap AP, (1993). Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25: 1461-1469.
55. Griffiths EJ, Halestrap AP, (1995). Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307: 93-98.
56. Gross ER, Hsu AK, Gross GJ, (2004). Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 94: 960-966.
57. Gross GJ, Auchampach JA, (1992). Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70: 223-233.
58. Hahn J-Y, Song YB, Kim EK, Yu CW, Bae J-W, Chung W-Y, et al. (2013). Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation 128: 1889-1896.
59. + channel activation by nitric oxide and protein kinase G in rabbit ventricular myocytes. Am J Physiol Heart Circ Physiol 283: H1545-H1554.
60. Hausenloy DJ, Yellon DM, (2004). New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460.
61. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM, (2002). Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534-543.
62. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM, (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976.
63. Hausenloy DJ, Ong S-B, Yellon DM, (2009). The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 104: 189-202.
64. Hearse DJ, Humphrey SM, Chain EB, (1973). Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. J Mol Cell Cardiol 5: 395-407.
65. Heinzel FR, Luo Y, Li X, Boengler K, Buechert A, García-Dorado D, et al. (2005). Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 97: 583-586.
66. Heusch G, Musiolik J, Gedik N, Skyschally A, (2011). Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 109: 1302-1308.
67. Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, et al. (2013). Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 128: 1495-1503.
68. Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K-i, Bouley DM, et al. (2003a). Inhibition of δ-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108: 2304-2307.
69. Inagaki K, Hahn HS, Dorn GW II, Mochly-Rosen D, (2003b). Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator. Circulation 108: 869-875.
70. + channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res 99: 878-883.
71. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR, (1984). Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 54: 277-285.
72. Juhaszova M, Zorov DB, Kim S-H, Pepe S, Fu Q, Fishbein KW, et al. (2004). Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549.
73. Karliner JS, (2013). Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 1831: 203-212.
74. Kingma JG Jr, Plante S, Bogaty P, (2000). Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion. J Am Coll Cardiol 36: 2317-2324.
75. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T, (1993). Ischemic preconditioning increases adenosine release and 5-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation 87: 208-215.
76. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. (2007). Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370: 1483-1493.
77. Knapp M, (2011). Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 62: 601-607.
78. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, et al. (2001). A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther 297: 254-259.
79. Korichneva I, Hoyos B, Chua R, Levi E, Hammerling U, (2002). Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. J Biol Chem 277: 44327-44331.
80. Krieg T, Qin Q, McIntosh EC, Cohen MV, Downey JM, (2002). ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol Heart Circ Physiol 283: H2322-H2330.
81. Krieg T, Cui L, Qin Q, Cohen MV, Downey JM, (2004). Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. J Mol Cell Cardiol 36: 435-443.
82. Krieg T, Liu Y, Rütz T, Methner C, Yang X-M, Dost T, et al. (2009). BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J 30: 1607-1613.
83. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN, (2004). Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 43: 276-283.
84. 2b-dependent signaling during early reperfusion. J Mol Cell Cardiol 43: 262-271.
85. 2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 295: H1288-H1295.
86. Lacerda L, Somers S, Opie LH, Lecour S, (2009). Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208.
87. Lecour S, (2009). Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47: 32-40.
88. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN, (2002). Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 34: 509-518.
89. Lecour S, Rochette L, Opie L, (2005a). Free radicals trigger TNFα-induced cardioprotection. Cardiovasc Res 65: 239-243.
90. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, et al. (2005b). Pharmacological preconditioning with tumor necrosis factor-α activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112: 3911-3918.
91. Levy DE, Lee C-k, (2002). What does Stat3 do? J Clin Invest 109: 1143-1148.
92. Li H, Takizawa H, Gong X, Concepcion A, Kambayashi J, Tandon N, et al. (2007). Platelet glycoprotein VI (GPVI) deletion reduces myocardial infarction in mice. Circulation 116 (Suppl. II): II-200.
93. Liao Z, Brar BK, Cai Q, Stephanou A, O'Leary RM, Pennica D, et al. (2002). Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 53: 902-910.
94. Lim SY, Hausenloy DJ, (2012). Remote ischemic conditioning: from bench to bedside. Front Physiol 3: 27.
95. Limalanathan S, Andersen GØ, Kløw N-E, Abdelnoor M, Hoffmann P, Eritsland J, (2014). Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI: results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc 3: e000679.
96. Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, et al. (2014). Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. Eur Heart J 35: 2516-2523.
97. 1 adenosine receptors in rabbit heart. Circulation 84: 350-356.
98. Liu Y, Downey JM, (1992). Ischemic preconditioning protects against infarction in rat heart. Am J Physiol Heart Circ Physiol 263: H1107-H1112.
99. Liu Y, Sato T, O'Rourke B, Marban E, (1998). Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 97: 2463-2469.
100. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, et al. (2012). Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 5: 288-295.
101. Ma X-L, Weyrich AS, Krantz S, Lefer AM, (1992). Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther 260: 1229-1236.
102. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. (1999). Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. J Am Coll Cardiol 34: 1711-1720.
103. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, et al. (1971). Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43: 67-82.
104. Maroko PR, Libby P, Bloor CM, Sobel BE, Braunwald E, (1972). Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. Circulation 46: 430-437.
105. Martin BJ, McClanahan TB, Van Wylen DGL, Gallagher KP, (1997). Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size. Basic Res Cardiol 92: 240-251.
106. Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, et al. (2008). Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 85: 1261-1270.
107. Methner C, Donat U, Felix SB, Krieg T, (2009). Cardioprotection of bradykinin at reperfusion involves transactivation of the epidermal growth factor receptor via matrix metalloproteinase-8. Acta Physiol (Oxf) 197: 265-271.
108. 2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 299: H1262-H1264.
109. Miki T, Cohen MV, Downey JM, (1998a). Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 186: 3-12.
110. Miki T, Liu GS, Cohen MV, Downey JM, (1998b). Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction? Basic Res Cardiol 93: 372-383.
111. Mirabet M, Garcia-Dorado D, Inserte J, Barrabés JA, Lidõn R-M, Soriano B, et al. (2002). Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol 283: H1134-H1141.
112. + exchange inhibitor, Hoe 642: difference from preconditioning in the role of protein kinase C. J Am Coll Cardiol 29: 693-701.
113. Montrucchio G, Alloatti G, Mariano F, De Paulis R, Comino A, Emanuelli G, et al. (1990). Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol 137: 71-83.
114. Murry CE, Jennings RB, Reimer KA, (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
115. Myers MG Jr, (2009). Moonlighting in mitochondria. Science 323: 723-724.
116. Nakano A, Liu GS, Heusch G, Downey JM, Cohen MV, (2000). Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 32: 1159-1167.
117. Nash MS, Wood JPM, Osborne NN, (1997). Protein kinase C activation by serotonin potentiates agonist-induced stimulation of cAMP production in cultured rat retinal pigment epithelial cells. Exp Eye Res 64: 249-255.
118. Nordstedt C, Kvanta A, Van der Ploeg I, Fredholm BB, (1989). Dual effects of protein kinase-C on receptor-stimulated cAMP accumulation in a human T-cell leukemia line. Eur J Pharmacol 172: 51-60.
119. Norton ED, Jackson EK, Virmani R, Forman MB, (1991). Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J 122: 1283-1291.
120. 2-receptor agonists on myocardial reperfusion injury. Am Heart J 123: 332-338.
121. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, et al. (1987). Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76: 1135-1145.
122. i proteins, phosphatidylinositol 3-kinase and tyrosine kinase. Cardiovasc Res 55: 544-552.
123. ATP channel opening. J Mol Cell Cardiol 35: 653-660.
124. ATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 286: H468-H476.
125. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 87: 460-466.
126. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. (2004). Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662.
127. Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, et al. (2011). Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 58: 1592-1599.
128. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
129. Pedretti S, Raddatz E, (2011). STAT3α interacts with nuclear GSK3beta and cytoplasmic RISK pathway and stabilizes rhythm in the anoxic-reoxygenated embryonic heart. Basic Res Cardiol 106: 355-369.
130. Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, Mognetti B, et al. (2005). Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 288: H2512-H2520.
131. Penna C, Bassino E, Alloatti G, (2011). Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med 236: 390-401.
132. Penna C, Angotti C, Pagliaro P, (2014). Protein S-nitrosylation in preconditioning and postconditioning. Exp Biol Med 239: 647-662.
133. Philipp S, Yang X-M, Willenbrock R, Downey JM, Cohen MV, (2005). Postconditioning must be initiated in less than 1 minute following reperfusion and is dependent on adenosine 2b receptors and PI3-kinase. Z Kardiol 94 (Suppl. 1): V803.
134. 2b receptor cascade. Cardiovasc Res 70: 308-314.
135. Ping P, Song C, Zhang J, Guo Y, Cao X, Li RCX, et al. (2002). Formation of protein kinase Cε-Lck signaling modules confers cardioprotection. J Clin Invest 109: 499-507.
136. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. (2008). Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481.
137. Pitarys CJ II, Virmani R, Vildibill HD Jr, Jackson EK, Forman MB, (1991). Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83: 237-247.
138. Pravdic D, Sedlic F, Mio Y, Vladic N, Bienengraeber M, Bosnjak ZJ, (2009). Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein kinase C-ε-mediated pathway. Anesthesiology 111: 267-274.
139. Qin Q, Downey JM, Cohen MV, (2003). Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase. Am J Physiol Heart Circ Physiol 284: H727-H734.
140. ATP-dependent mechanism. Am J Physiol Heart Circ Physiol 287: H712-H718.
141. Reimer KA, Jennings RB, (1984). Can we really quantitate myocardial cell injury? In:, Hearse DJ, Yellon DM, (eds). Therapeutic Approaches to Myocardial Infarct Size Limitation. Raven Press: New York, pp. 163-184.
142. Reimer KA, Murry CE, Richard VJ, (1989). The role of neutrophils and free radicals in the ischemic-reperfused heart: why the confusion and controversy? J Mol Cell Cardiol 21: 1225-1239.
143. Rischard F, McKean T, (1998). Ischemia and ischemic preconditioning in the buffer-perfused pigeon heart. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 119: 59-65.
144. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, (2005). A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775-1780.
145. Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, et al. (2012). Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol 107: 275.
146. Sabatine MS, Cannon CP, Gibson CM, Lõpez-Sendõn JL, Montalescot G, Theroux P, et al. (2005a). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179-1189.
147. Sabatine MS, Cannon CP, Gibson CM, Lõpez-Sendõn JL, Montalescot G, Theroux P, et al. (2005b). Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294: 1224-1232.
148. 1 receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 29: 682-688.
149. 3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty. Cardiovasc Res 66: 552-561.
150. Sala-Mercado JA, Wider J, Undyala VVR, Jahania S, Yoo W, Mentzer RM Jr, et al. (2010). Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. Circulation 122 (Suppl. 1): S179-S184.
151. Schott RJ, Rohmann S, Braun ER, Schaper W, (1990). Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 66: 1133-1142.
152. Schulman D, Latchman DS, Yellon DM, (2002). Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283: H1481-H1488.
153. Schultz JE, Rose E, Yao Z, Gross GJ, (1995). Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268: H2157-H2161.
154. Schwanke U, Konietzka I, Duschin A, Li X, Schulz R, Heusch G, (2002). No ischemic preconditioning in heterozygous connexin43-deficient mice. Am J Physiol Heart Circ Physiol 283: H1740-H1742.
155. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, et al. (2009a). Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104: 15-18.
156. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G, (2009b). Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104: 469-483.
157. Smith RM, Suleman N, McCarthy J, Sack MN, (2002). Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFα gene. Cardiovasc Res 55: 553-560.
158. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S, (2012). Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 26: 227-237.
159. Sörensson P, Saleh N, Bouvier F, Böhm F, Settergren M, Caidahl K, et al. (2010). Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 96: 1710-1715.
160. Squadrito F, Altavilla D, Squadrito G, Saitta A, Campo GM, Arlotta M, et al. (1999). Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Eur J Pharmacol 364: 159-168.
161. Srisakuldee W, Jeyaraman MM, Nickel BE, Tanguy S, Jiang Z-S, Kardami E, (2009). Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res 83: 672-681.
162. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. (2005). Postconditioning the human heart. Circulation 112: 2143-2148.
163. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. (1998). Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-714.
164. Sun J, Aponte AM, Kohr MJ, Tong G, Steenbergen C, Murphy E, (2013). Essential role of nitric oxide in acute ischemic preconditioning: S-nitros(yl)ation versus sGC/cGMP/PKG signaling? Free Radic Biol Med 54: 105-112.
165. Swyers T, Redford D, Larson DF, (2014). Volatile anesthetic-induced preconditioning. Perfusion 29: 10-15.
166. Takaya N, Katoh Y, Iwabuchi K, Hayashi I, Konishi H, Itoh S, et al. (2005). Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor γ-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 39: 856-864.
167. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC, (2004). Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 100: 707-721.
168. Tarantini G, Favaretto E, Marra MP, Frigo AC, Napodano M, Cacciavillani L, et al. (2012). Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int J Cardiol 162: 33-38.
169. Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, et al. (2000). Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation 102: 3032-3038.
170. Tissier R, Cohen MV, Downey JM, (2007a). Protecting the acutely ischemic myocardium beyond reperfusion therapies: are we any closer to realizing the dream of infarct size elimination? Arch Mal Coeur Vaiss 100: 794-802.
171. Tissier R, Hamanaka K, Kuno A, Parker JC, Cohen MV, Downey JM, (2007b). Total liquid ventilation provides ultra-fast cardioprotective cooling. J Am Coll Cardiol 49: 601-605.
172. Tong H, Imahashi K, Steenbergen C, Murphy E, (2002). Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377-379.
173. Toombs CF, Wiltse AL, Shebuski RJ, (1993). Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium. Implication of norepinephrine release in the preconditioning effect. Circulation 88: 2351-2358.
174. Trincavelli ML, Marroni M, Tuscano D, Ceruti S, Mazzola A, Mitro N, et al. (2004). Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. J Neurochem 91: 1180-1190.
175. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJT, Willems GM, et al. (1993). Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 22: 407-416.
176. Van Winkle DM, Thornton JD, Downey DM, Downey JM, (1991). The natural history of preconditioning: cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Artery Dis 2: 613-619.
177. Vander Heide RS, Reimer KA, (1996). Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 31: 711-718.
178. Vegh A, Szekeres L, Parratt J, (1992). Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 107: 648-652.
179. Velasco CE, Turner M, Cobb MA, Virmani R, Forman MB, (1991). Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. Am Heart J 122: 1561-1570.
180. Wall TM, Sheehy R, Hartman JC, (1994). Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270: 681-689.
181. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
182. Wegrzyn J, Potla R, Chwae Y-J, Sepuri NBV, Zhang Q, Koeck T, et al. (2009). Function of mitochondrial Stat3 in cellular respiration. Science 323: 793-797.
183. q knock-out mice in vivo. J Mol Cell Cardiol 44: 143-150.
184. Weselcouch EO, Baird AJ, Sleph P, Grover GJ, (1995). Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts. Am J Physiol Heart Circ Physiol 268: H242-H249.
185. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
186. 2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 47: 684-690.
187. Xu Z, Yang X-M, Cohen MV, Neumann T, Heusch G, Downey JM, (2000). Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol 32: 2339-2347.
188. Xu Z, Jiao Z, Cohen MV, Downey JM, (2002). Protection from AMP 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. J Cardiovasc Pharmacol 40: 510-518.
189. Xu Z, Downey JM, Cohen MV, (2003). Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 5: 368-371.
190. Yang X-M, Krieg T, Cui L, Downey JM, Cohen MV, (2004a). NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36: 411-421.
191. Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV, (2004b). Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110.
192. Yang X-M, Philipp S, Downey JM, Cohen MV, (2005). Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100: 57-63.
193. Yang X-M, Philipp S, Downey JM, Cohen MV, (2006a). Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101: 311-318.
194. Yang X-M, Liu Y, Liu Y, Tandon N, Kambayashi J, Downey JM, et al. (2010). Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. Basic Res Cardiol 105: 119-128.
195. Yang X-M, Cui L, Alhammouri A, Downey JM, Cohen MV, (2013a). Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther 27: 403-412.
196. Yang X-M, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. (2013b). Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 27: 109-115.
197. 12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 18: 251-262.
198. Yang Y-J, Zhao J-L, You S-J, Wu Y-J, Jing Z-C, Yang W-X, et al. (2006b). Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 92: 1131-1137.
199. Yellon DM, Alkhulaifi AM, Browne EE, Pugsley WB, (1992). Ischaemic preconditioning limits infarct size in the rat heart. Cardiovasc Res 26: 983-987.
200. Ytrehus K, Liu Y, Downey JM, (1994). Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol Heart Circ Physiol 266: H1145-H1152.
201. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502.
202. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective effects of eniporide in Acute Myocardial Infarction (ESCAMI) trial. J Am Coll Cardiol 38: 1644-1650.
203. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, et al. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588.